BayCare Proton Center Achieves Landmark First Patient Treatment with Upright Proton Therapy

BayCare Proton Center Launches Upright Proton Therapy

In a significant advancement in cancer treatment, the BayCare Proton Center has successfully treated its first patient using the innovative upright proton therapy. This marks an important milestone for the clinic and demonstrates their commitment to improving access to cutting-edge cancer care for the communities they serve.

Located within the Fred J. Woods Radiation Therapy Center on the St. Joseph's Hospital campus in Tampa, Florida, the BayCare Proton Center is the second establishment in the world to utilize this revolutionary treatment technology. The therapy was conducted using the MEVION S250-FIT™, a compact proton therapy system developed by Mevion Medical Systems, which integrates Leo Cancer Care's Marie® upright patient positioning and imaging solution.

Transforming Patient Experience

The introduction of upright proton therapy signifies a fundamental shift in how patients are positioned during treatment. Traditionally, proton therapy required patients to lie flat on a treatment table. However, with the Marie® solution, patients are able to receive treatment in an upright position, whether seated or perched, optimizing comfort and fostering a more engaging environment for both patients and radiation therapists. This setup enhances communication and interaction during treatment, ultimately resulting in a patient-centered approach to care.

Innovative Design and Technology

The BayCare Proton Center's technology is designed around an ultra-compact, fixed-beam proton accelerator paired with a rotational, upright patient chair. This design allows hospitals to introduce proton therapy without the extensive infrastructure typically associated with larger, gantry-based systems. The compactness of the MEVION S250-FIT™ means that it can fit into standard linear accelerator vaults, making it feasible for more hospitals to adopt.

Dr. John Greskovich, Medical Director of the BayCare Department of Radiation Oncology, stated, "Treating the first patient on our innovative proton therapy system marks a transformational milestone for BayCare Cancer Institute. Our patients in West Central Florida can now access proton therapy locally, reducing the need for travel to distant facilities for this advanced treatment."

A New Era in Proton Therapy

CEO of Leo Cancer Care, Stephen Towe, highlighted the importance of this milestone by saying, "BayCare reaching this milestone is about much more than treating a first patient. It demonstrates what becomes possible when we rethink both the size of the proton therapy system and the way we position the patient." Towe believes that this combination of innovation can bring advanced, patient-centered proton therapy into more hospitals and closer to the communities they serve.

Tina Yu, PhD, President and CEO of Mevion Medical Systems, emphasized the MEVION S250-FIT's design objectives that challenge traditional infrastructure requirements. She stated, "Seeing BayCare bring the FIT system into clinical use in a standard LINAC-sized vault, with Leo Cancer Care's Marie® integrated, shows what compact proton therapy with upright treatment can deliver."

Commitment to Community Health

BayCare Cancer Institute is part of the broader BayCare Health System, a not-for-profit academic health care network serving Tampa Bay and the greater West Central Florida region. The initiative to incorporate advanced treatment technologies like upright proton therapy showcases BayCare’s commitment to enhancing health services for its communities.

As this technology continues to develop, the BayCare Proton Center aims not only to lead in cancer treatment innovation but also to contribute significantly to the overall improvement of healthcare accessibility and quality in Florida. For more information about BayCare and its offerings, please visit BayCare.org.

In conclusion, the success of the BayCare Proton Center's first patient treated with upright proton therapy marks a noteworthy advancement in the field of oncology, showcasing a future where access to life-saving treatments is more readily available for patients in their own communities.